Regeneron Pharmaceuticals Q2-Q3 Confirmed "Troughing in Progress
IF we do not crash like many Elliottsions are suggesting implying of Grand 5th wave since 1929...
iF we do not start WW3...
IF everything utterly absolute out there in the pharmaceutical industries locally
and globally...
IF our studies of the relation between XLV and Regeneron Pharmaceuticals is
remotely correct...
Then we should have struck a trough or we shall see one in the next few months
Q2-Q4 = We will see a big bullish move next !
*** Risk down is (-35%) ...
iF we do not start WW3...
IF everything utterly absolute out there in the pharmaceutical industries locally
and globally...
IF our studies of the relation between XLV and Regeneron Pharmaceuticals is
remotely correct...
Then we should have struck a trough or we shall see one in the next few months
Q2-Q4 = We will see a big bullish move next !
*** Risk down is (-35%) ...
Trade active
*** Risk down is (-35%) ...Trade closed: target reached
Note
Note
Risk down (-35%)Any similarity out there !!!
I do more in depth studies of stocks on my twitter account. Hope you would enjoy it there as you are enjoying it here.
****** Past performance is no guarantee of future results***
twitter.com/samitrading1
****** Past performance is no guarantee of future results***
twitter.com/samitrading1
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
I do more in depth studies of stocks on my twitter account. Hope you would enjoy it there as you are enjoying it here.
****** Past performance is no guarantee of future results***
twitter.com/samitrading1
****** Past performance is no guarantee of future results***
twitter.com/samitrading1
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.